Kairos Pharma, Ltd. will implement a 1-for-7 Reverse Stock Split effective September 1, 2026, reducing outstanding shares to align with trading requirements. This action aims to enhance the per-share trading price and maintain compliance with NYSE American listing standards.

Key Highlights

  • The reverse stock split will convert every seven outstanding shares into one share.
  • The effective date for trading on a split-adjusted basis is set for September 1, 2026.
  • The new CUSIP number for shares following the split will be 48301N203.

Kairos Pharma, Ltd. (AMEX: KAPA) will conduct a 1-for-7 reverse stock split of its outstanding common stock, effective September 1, 2026. This strategic move is designed to modify the share structure by transforming every seven shares into one, thereby adjusting the Market Price per share. The reverse split will help the company align with the necessary trading requirements set forth by the NYSE American, important for maintaining its listing status.

The restructuring underscores the company's efforts to improve investor confidence and enhance trading vitality following stockholder approval at the June 29, 2026, annual meeting.

Split Mechanics Defined

Following the reverse stock split, every stockholder will see their shares consolidated at a ratio where seven shares convert into one share of common stock valued at $0.001 per share. The action will not alter the total number of authorized shares, which remains at a total of 120,000,000 shares, classified as 100,000,000 common and 20,000,000 preferred shares. There will be no issuance of fractional shares; instead, shareholders entitled to a fraction will receive one full share.

VStock Transfer LLC will manage the exchange process efficiently for stockholders holding shares in both registered and book-entry forms.

Implications for Shareholder Value

The reverse stock split is anticipated to augment the per-share trading price without impacting shareholders' overall percentage interest in the company. The adjusted trading price is significant as it allows Kairos Pharma to meet the minimum trading price requirement set forth by the NYSE American. After the split, adjustments will also occur in the outstanding convertible notes, warrants, and restricted stock units, maintaining proportionality in their exercise prices.

This measure is believed to facilitate future Capital raising and improve the company's marketability to institutional investors.

Next Steps to Monitor

As the effective date approaches, investors will be closely observing how the reverse stock split affects trading dynamics as of September 1, 2026. Kairos Pharma plans to trade on a split-adjusted basis commencing on this date. Shareholders will experience these changes without needing to take any action, as conversion adjustments will be automatic for stock held in “street name.” These upcoming changes in Liquidity and trading Volume could significantly impact both investor sentiment and the company's stock performance in the short term.

Peers Moving on This News

  • Apimeds Pharmaceuticals US, Inc. (AMEX: APUS) down 6.0%
  • Ensysce Biosciences, Inc. (NASDAQ: ENSC) down 2.0%